Lilly Statement on Contribution to Indiana Biosciences Research Institute
INDIANAPOLIS, Nov. 19, 2013
INDIANAPOLIS, Nov. 19, 2013 /PRNewswire/ -- Following is a statement from John
C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and
Company (NYSE: LLY), on the company's investment of $7.5 million toward
startup of the Indiana Biosciences Research Institute.
"Today's announcement represents a significant investment by Lilly in the
future of Indiana and in the future of biosciences research. Each year in
Indiana, billions of dollars are invested in research and development to
advance medical innovation. This institute will help Indiana attract
additional global talent and will nurture partnerships across the state and
across the country - keeping more research dollars in Indiana and attracting
more federal research funds to our state.
"In the last decade, Indiana has come of age as a recognized leader in the
life sciences - with demonstrated capabilities in biopharmaceuticals, medical
devices, and diagnostics, as well as in the areas of animal health and crop
sciences. The research institute will fuel Indiana's economy and will
underscore the state's position as a life sciences leader. The bio-landscape
of Indiana is fertile ground for the Institute, and Lilly is proud to be a
part of it.
"The IBRI is an R&D model that will help us address some of our most pressing
medical needs. Despite important advances in recent years, diseases such as
diabetes continue to affect our citizens at alarming rates. By pulling
together the best minds for collaborative thinking and research, the new
institute will help move us closer to solving some of the world's most
difficult challenges in health and nutrition."
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers –
through medicines and information– for some of the world's most urgent
medical needs. Additional information about Lilly is available at
Refer to: (317) 277-4021; Greg Kueterman; email@example.com
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
Press spacebar to pause and continue. Press esc to stop.